Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Binimetinib (ARRY-162) 是一种可口服的选择性 MEK1/2抑制剂,抑制MEK 的IC50为 12 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 163 | 现货 | ||
5 mg | ¥ 356 | 现货 | ||
10 mg | ¥ 572 | 现货 | ||
25 mg | ¥ 993 | 现货 | ||
50 mg | ¥ 1,580 | 现货 | ||
100 mg | ¥ 2,390 | 现货 | ||
200 mg | ¥ 3,820 | 现货 | ||
500 mg | ¥ 5,950 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 398 | 现货 |
产品描述 | Binimetinib (ARRY-162) (MEK162, ARRY-162, ARRY-438162) is an orally available inhibitor of MEK1/2 (IC50: 12 nM) in a cell-free assay. |
靶点活性 | MEK:12 nM |
体外活性 | 在大鼠胶原诱导性关节炎模型中,ARRY-438162(1/3 mg/kg,2次/天,p.o.)抑制踝关节直径增加(27%/50%),而布洛芬处理可抑制46%.在大鼠佐剂诱发性关节炎模型中,ARRY-438162(3/10 mg/kg)抑制AIA踝关节直径(11%/34%).在注射MCF7-RSK4细胞的免疫缺陷小鼠,ARRY-438162(6 mg/kg,2次/天)与BEZ235联用可使肿瘤生长显著降低.在大鼠佐剂诱发性关节炎模型中,与对照组相比,ARRY-438162(10 mg/kg)剂量依赖地完全抑制血清中IL-6浓度.处理在大鼠胶原诱导性关节炎和佐剂诱发性关节炎模型中,ARRY-438162(10 mg/kg,2次/天p.o.)剂量依赖性地使疾病的严重程度降低.同样剂量处理大鼠胶原诱导性关节炎模型,可显著抑制病变(炎症,软骨损伤,血管翳形成,和骨重吸收), ARRY-438162(1/3 mg/kg)处理则分别抑制32%和60%.处理在大鼠佐剂诱发性关节炎模型中,与对照组相比,ARRY-438162(10/30 mg/kg)剂量依赖性地显著抑制踝关节肿胀. |
体内活性 | ARRY-438162是ATP非竞争性的MEK1/2抑制剂,可抑制细胞内pERK(IC50:11 nM)。MEK162(1 μM)与MK-2206(2 μM)联用可完全逆转表达RSK的MCF7细胞的抗性。ARRY-438162(2 μM)对成骨细胞分化的影响微弱。 ARRY-438162(10 μM)抑制体外破骨细胞再吸收(IC50:625 nM)。ARRY-438162(625 nM)抑制体外破骨细胞分化(IC50:39 nM)。 |
细胞实验 | MEK162 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[2]. MCF7 cells infected as indicated are seeded in 12-well plates (2×104). After 24 hours, cells are treated with BEZ235 (100 or 200 nM), BKM120 (0.75 or 1 μM), GDC-0941 (1 μM), or MK2206 (2 μM) alone or in combination with MEK162 (1 μM), BI-D1870 (10 μM), or AZD6244 (1 μM), as indicated in text. Cell numbers are quantified by fixing cells with 4% glutaraldehyde or methanol, washing the cells twice in Water, and staining the cells with 0.1% crystal violet. The dye is subsequently extracted with 10% acetic acid, and its absorbance is determined (570 nm). Growth curves are performed in triplicate. Viability assays with CellTiter-Glo are performed by plating 2,000 cells in 96-well plates, adding the drug at 24 hours, and assaying 4 to 5 days after drug addition. Cell-cycle and hypodiploid apoptotic cells are quantified by flow cytometry. Briefly, cells are washed with PBS, fixed in cold 70% ethanol, and then stained with propidium iodide while being treated with RNase. Quantitative analysis of sub-G1 cells is carried out in a FACScalibur cytometer using Cell Quest software[2]. |
别名 | ARRY-438162, ARRY-162, MEK162 |
分子量 | 441.23 |
分子式 | C17H15BrF2N4O3 |
CAS No. | 606143-89-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 82 mg/mL (185.8 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2664 mL | 11.332 mL | 22.6639 mL | 56.6598 mL |
5 mM | 0.4533 mL | 2.2664 mL | 4.5328 mL | 11.332 mL | |
10 mM | 0.2266 mL | 1.1332 mL | 2.2664 mL | 5.666 mL | |
20 mM | 0.1133 mL | 0.5666 mL | 1.1332 mL | 2.833 mL | |
50 mM | 0.0453 mL | 0.2266 mL | 0.4533 mL | 1.1332 mL | |
100 mM | 0.0227 mL | 0.1133 mL | 0.2266 mL | 0.5666 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Binimetinib 606143-89-9 Autophagy MAPK MEK Inhibitor MEK-162 Mitogen-activated protein kinase kinase MEK 162 ARRY 162 ARRY162 ARRY438162 MAPKK MAP2K ARRY 438162 ARRY-438162 inhibit ARRY-162 MEK162 inhibitor